J&J Medical Connect
CAPLYTA®

(lumateperone)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

CAPLYTA - Adverse Event - Hyponatremia

Last Updated: 11/03/2026

SUMMARY

  • Low sodium (<130 mEq/L) was a chemistry laboratory parameter that was evaluated as a potentially clinically significant (PCS) criterion in CAPLYTA clinical trials. Safety assessments also included treatment-emergent adverse events (TEAEs) for
    hyponatremia.1-14

Major Depressive Disorder

  • Durgam et al (2025)1 conducted a phase 3 study (Study 501) assessing CAPLYTA 42 mg adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD); PCS low sodium was reported in 3 patients (1.3%) receiving CAPLYTA 42 mg+ADT and no patients receiving placebo+ADT.
  • Durgam et al (2025)2 conducted a phase 3 study (Study 502) evaluating CAPLYTA 42 mg adjunctive to ADT in patients with MDD; PCS low sodium was reported in 1 patient (0.5%) receiving CAPLYTA 42 mg+ADT and no patients receiving placebo+ADT.
  • In a pooled safety analysis of Study 501 and Study 502, no TEAEs for hyponatremia were reported.15
  • Durgam et al (2026)3 conducted an open-label (OL) study (Study 503) that evaluated CAPLYTA 42 mg adjunctive to ADT in patients with MDD; PCS low sodium was reported in 0.5% of patients receiving CAPLYTA 42 mg+ADT. There was an event of mild TEAE of hyponatremia.4,15

Bipolar Depression

  • Tohen et al (2026)5 reported the results of a 6-month OL period of a phase 3 study (Study 401) assessing CAPLYTA 42 mg in patients with major depressive episodes (MDEs) associated with bipolar I or bipolar II disorder; no events of low sodium or TEAEs for hyponatremia were reported.
  • Suppes et al (2023)6 conducted a phase 3 study (Study 402) assessing lumateperone adjunctive to lithium or valproate in patients with MDEs associated with bipolar I or bipolar II disorder; PCS low sodium was reported in 4 patients (2.3%) receiving CAPLYTA 42 mg, 1 patient (0.6%) receiving lumateperone 28 mg, and 2 patients (1.2%) receiving placebo.7 No TEAEs for hyponatremia were reported.
  • Calabrese et al (2021)8 conducted a phase 3 study (Study 404) assessing CAPLYTA 42 mg for the treatment of MDEs associated with bipolar I and bipolar II disorder; PCS low sodium was reported in 1 (0.5%) patient receiving CAPLYTA 42 mg and 1 (0.5%) patient receiving placebo.9 There were no TEAEs for hyponatremia reported.

Schizophrenia

  • Kane et al (2021)10 conducted a pooled analysis of 3 randomized studies assessing CAPLYTA 42 mg in patients with schizophrenia; low sodium was not reported in patients who received CAPLYTA 42 mg and there were no TEAEs for hyponatremia.11
  • There were no reports of syndrome of inappropriate antidiuretic hormone (SIADH) adverse events in CAPLYTA clinical trials across all indications (adjunctive MDD, bipolar I or II disorder, and schizophrenia).

PRODUCT LABELING

Geriatric Use

The use of serotonin reuptake inhibitors (SRIs) has been associated with clinically significant hyponatremia in geriatric patients, who may be at greater risk for this adverse reaction. The concomitant use of CAPLYTA with an SRI may increase this risk.16 

CLINICAL DATA

Major Depressive Disorder

Study 501

Durgam et al (2025)1 conducted a phase 3, 6-week, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study to assess the efficacy and safety of CAPLYTA 42 mg adjunctive to ADT in patients with MDD who had an inadequate response to ADT (CAPLYTA 42 mg+ADT, n=241; placebo+ADT, n=243). In patients with available non-PCS baseline values and at least 1 postbaseline assessment (N1), 3 patients (1.3%) receiving CAPLYTA 42 mg+ADT (N1=230) and no patients receiving placebo+ADT met the criteria for PCS low sodium.12

Study 502

Durgam et al (2025)2 conducted a phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, international study to evaluate the efficacy and safety of CAPLYTA 42 mg adjunctive to ADT in patients with MDD who had an inadequate response to ADT (CAPLYTA 42 mg+ADT, n=242; placebo+ADT, n=238). The number of patients who met the PCS criteria for low sodium was 1 patient (0.5%) receiving CAPLYTA 42 mg+ADT (N1=211) and no patients receiving placebo+ADT.13

Pooled Safety Analysis (Study 501 and Study 502)

In a pooled safety analysis, all decreases in sodium found in Study 501 and Study 502 were transient and normalized at subsequent laboratory assessment with continued drug administration. No TEAEs for hyponatremia were reported.15 

Study 503

Durgam et al (2026)3 conducted a 26-week, OL study that evaluated the long-term safety and tolerability of CAPLYTA 42 mg adjunctive to ADT in patients with MDD who had completed Study 501 or Study 502 (N=809). The 26-week OL treatment period was followed by a 2-week safety follow-up period. The incidence of patients who met the PCS criteria for low sodium and received CAPLYTA 42 mg+ADT was 0.5% (n=4/N1=777) during the open-label treatment period (OLTP). One patient treated with CAPLYTA (N=809) had a TEAE of hyponatremia.4 The TEAE was related to study drug, mild in severity, and resolved with continued administration during the OLTP.15 

Bipolar Depression

Study 401

Tohen et al (2026)5 reported the results of a 6-month OL period of a phase 3 study that assessed the long-term safety of CAPLYTA 42 mg in patients with MDEs associated with bipolar I or bipolar II disorder (N=127). CAPLYTA 42 mg was administered once daily for up to 175 days; this was followed by a 2-week safety follow-up period. There were no reports of low sodium or TEAEs for hyponatremia in the open-label follow-up period.14 

Study 402

Suppes et al (2023)6 conducted a phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of lumateperone adjunctive to lithium or valproate in patients with MDEs associated with bipolar I or bipolar II disorder (CAPLYTA 42 mg, n=177; lumateperone 28 mg, n=176; placebo, n=175). Treatment was administered once daily for 6 weeks. Safety was assessed weekly and approximately 2 weeks after the last study dose. In patients who were reported to not have a markedly abnormal value at baseline and had at least 1 postbaseline value (N1), PCS low sodium was reported in 4 patients (2.3%) receiving CAPLYTA 42 mg (N1=173), 1 patient (0.6%) receiving lumateperone 28 mg (N1=172), and 2 patients (1.2%) receiving placebo (N1=173).7 There were no TEAEs for hyponatremia reported.

Study 404

Calabrese et al (2021)8 conducted a phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of CAPLYTA 42 mg for the treatment of MDEs associated with bipolar I and bipolar II disorder (CAPLYTA 42 mg, n=188; placebo, n=189). Safety was assessed weekly and approximately 2 weeks after the last study dose. PCS low sodium was reported in 1 (0.5%) patient receiving CAPLYTA 42 mg (N1=187) and 1 (0.5%) patient receiving placebo (N1=188).9 There were no TEAEs for hyponatremia reported.

Schizophrenia

Pooled Safety Analysis (Study 005, Study 301, and Study 302)

Kane et al (2021)10 conducted a pooled analysis of 3 randomized, double-blind, placebo-controlled studies to assess the efficacy, safety, and tolerability of CAPLYTA 42 mg in patients with schizophrenia (CAPLYTA 42 mg, n=406; placebo, n=412; risperidone 4 mg, n=255). Patients were treated with CAPLYTA 42 mg once daily for 4 weeks in Study 005 and Study 301 and for 6 weeks in Study 302. Safety was assessed at baseline, weekly on-treatment, and at the end of the study. Low sodium was not reported in patients who received CAPLYTA 42 mg and there were no TEAEs for hyponatremia.11 

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, and DERWENT® (and/or other resources, including internal/external databases) was conducted on 22 October 2026.

References

1 Durgam S, Earley WR, Kozauer SG, et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry. 2025;86(4):25m15848.  
2 Durgam S, Earley WR, Kozauer SG, et al. Adjunctive lumateperone in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. Am J Psychiatry. 2025;182(12):1072-1082.  
3 Durgam S, Earley WR, Kozauer SG, et al. Long-term adjunctive lumateperone 42 mg treatment in major depressive disorder: results from a 6-month open-label extension study. Eur Neuropsychopharmacol. 2026;108:112786.  
4 Data on File. CAPLYTA. Clinical Study Report of Study 503. Intra-Cellular Therapies, Inc; 2025.  
5 Tohen M, Durgam S, Kozauer SG, et al. Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study. Int Clin Psychopharmacol. 2026;41(2):130-137.  
6 Suppes T, Durgam S, Kozauer SG, et al. Adjunctive lumateperone (ITI‐007) in the treatment of bipolar depression: results from a randomized placebo‐controlled clinical trial. Bipolar Disord. 2023;25(6):478-488.  
7 Data on File. CAPLYTA. Clinical Study Report of Study 402. Intra-Cellular Therapies, Inc; 2021.  
8 Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. Am J Psychiatry. 2021;178(12):1098-1106.  
9 Data on File. CAPLYTA. Clinical Study Report of Study 404. Intra-Cellular Therapies, Inc; 2020.  
10 Kane JM, Durgam S, Satlin A, et al. Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials. Int Clin Psychopharmacol. 2021;36(5):244-250.  
11 Data on File. CAPLYTA. Integrated Safety Summary. Intra-Cellular Therapies, Inc; 2019.  
12 Data on File. CAPLYTA. Clinical Study Report of Study 501. Intra-Cellular Therapies, Inc; 2024.  
13 Data on File. CAPLYTA. Clinical Study Report of Study 502. Intra-Cellular Therapies, Inc; 2024.  
14 Data on File. CAPLYTA. Clinical Study Report of Study 401. Intra-Cellular Therapies, Inc; 2021.  
15 Data on File. CAPLYTA. Medical Affairs Communication. Intra-Cellular Therapies, Inc.; 2025.  
16 CAPLYTA (lumateperone) [Prescribing Information]. Titusville, NJ: Intra-Cellular Therapies, Inc; https://www.intracellulartherapies.com/docs/caplyta_pi.pdf   

Would you like to clear and leave your conversation? Message history will be lost.